Atlas Invest | $25,000,000 | (Jan 22, 2026)
AiStrike | $7,000,000 | (Jan 22, 2026)
Zarminali Pediatrics | $110,000,000 | (Jan 22, 2026)
Certified by Founder
Lodge
Zura Bio Limited
start up
United States
- San Diego, CA
- 07/06/2023
- Unknown
- $80,000,000
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage. Zura Bio is headquartered in San Diego, CA with team members in the UK and USA.
- Industry Biotechnology Research
- Website https://zurabio.com/
- LinkedIn https://www.linkedin.com/company/zura-bio-limited/
Related People
Someit SidhuFounder
United Kingdom -
London, England
N/A
LinkedIn
https://www.linkedin.com/in/someit/
AnswersNow | $40,000,000 | (Jan 22, 2026)
Upscale AI(US) | $200,000,000 | (Jan 22, 2026)
Nasdaq Private Market | $37,600,000 | (Jan 22, 2026)
PraxisPro | $6,000,000 | (Jan 22, 2026)
furl | $10,000,000 | (Jan 22, 2026)
Statusphere | $18,000,000 | (Jan 21, 2026)
Think Bioscience | $55,000,000 | (Jan 21, 2026)
ErVimmune | $19,917,795 | (Jan 21, 2026)
Formulary Financial | $4,600,000 | (Jan 21, 2026)